The	the	O	O
effects	effects	O	O
of	of	O	O
the	the	O	O
adjunctive	adjunctive	O	O
bupropion	bupropion	S_chemicals	O
on	on	O	O
male	male	O	B_disease
sexual	sexual	O	B_disease
dysfunction	dysfunction	O	I_disease
induced	induced	O	O
by	by	O	O
a	a	O	O
selective	selective	B_chemicals	O
serotonin	serotonin	B_chemicals	O
reuptake	reuptake	B_chemicals	O
inhibitor	inhibitor	I_chemicals	O
:	:	O	O
a	a	O	O
double-blind	double-blind	O	O
placebo-controlled	placebo-controlled	O	O
and	and	O	O
randomized	randomized	O	O
study	study	O	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
determine	determine	O	O
the	the	O	O
safety	safety	O	O
and	and	O	O
efficacy	efficacy	O	O
of	of	O	O
adjunctive	adjunctive	O	O
bupropion	bupropion	S_chemicals	O
sustained-release	sustained-release	O	O
(	(	O	O
SR	sr	O	O
)	)	O	O
on	on	O	O
male	male	O	B_disease
sexual	sexual	O	B_disease
dysfunction	dysfunction	O	I_disease
(	(	O	O
SD	sd	O	O
)	)	O	O
induced	induced	O	O
by	by	O	O
a	a	O	O
selective	selective	B_chemicals	O
serotonin	serotonin	B_chemicals	O
reuptake	reuptake	B_chemicals	O
inhibitor	inhibitor	I_chemicals	O
(	(	O	O
SSRI	ssri	O	O
)	)	O	O
,	,	O	O
as	as	O	O
SD	sd	O	O
is	is	O	O
a	a	O	O
common	common	O	O
side-effect	side-effect	O	O
of	of	O	O
SSRIs	ssris	S_chemicals	O
and	and	O	O
the	the	O	O
most	most	O	O
effective	effective	O	O
treatments	treatments	O	O
have	have	O	O
yet	yet	O	O
to	to	O	O
be	be	O	O
determined	determined	O	O
.	.	O	O

PATIENTS	patients	O	O
AND	and	O	O
METHODS	methods	O	O
:	:	O	O
The	the	O	O
randomized	randomized	O	O
sample	sample	O	O
consisted	consisted	O	O
of	of	O	O
234	234	O	O
euthymic	euthymic	O	O
men	men	O	O
who	who	O	O
were	were	O	O
receiving	receiving	O	O
some	some	O	O
type	type	O	O
of	of	O	O
SSRI	ssri	O	O
.	.	O	O

The	the	O	O
men	men	O	O
were	were	O	O
randomly	randomly	O	O
assigned	assigned	O	O
to	to	O	O
bupropion	bupropion	S_chemicals	O
SR	sr	O	O
(	(	O	O
150	150	O	O
mg	mg	O	O
twice	twice	O	O
daily	daily	O	O
,	,	O	O
117	117	O	O
)	)	O	O
or	or	O	O
placebo	placebo	O	O
(	(	O	O
twice	twice	O	O
daily	daily	O	O
,	,	O	O
117	117	O	O
)	)	O	O
for	for	O	O
12	12	O	O
weeks	weeks	O	O
.	.	O	O

Efficacy	efficacy	O	O
was	was	O	O
evaluated	evaluated	O	O
using	using	O	O
the	the	O	O
Clinical	clinical	O	O
Global	global	O	O
Impression-Sexual	impression-sexual	O	O
Function	function	O	O
(	(	O	O
CGI-SF	cgi-sf	O	O
;	;	O	O
the	the	O	O
primary	primary	O	O
outcome	outcome	O	O
measure	measure	O	O
)	)	O	O
,	,	O	O
the	the	O	O
International	international	O	O
Index	index	O	O
of	of	O	O
Erectile	erectile	O	O
Function	function	O	O
(	(	O	O
IIEF	iief	O	O
)	)	O	O
,	,	O	O
Arizona	arizona	O	O
Sexual	sexual	O	O
Experience	experience	O	O
Scale	scale	O	O
(	(	O	O
ASEX	asex	O	O
)	)	O	O
,	,	O	O
and	and	O	O
Erectile	erectile	O	B_disease
Dysfunction	dysfunction	O	I_disease
Inventory	inventory	O	O
of	of	O	O
Treatment	treatment	O	O
Satisfaction	satisfaction	O	O
(	(	O	O
EDITS	edits	O	O
)	)	O	O
(	(	O	O
secondary	secondary	O	O
outcome	outcome	O	O
measures	measures	O	O
)	)	O	O
.	.	O	O

Participants	participants	O	O
were	were	O	O
followed	followed	O	O
biweekly	biweekly	O	O
during	during	O	O
study	study	O	O
period	period	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
After	after	O	O
12	12	O	O
weeks	weeks	O	O
of	of	O	O
treatment	treatment	O	O
,	,	O	O
the	the	O	O
mean	mean	O	O
(	(	O	O
sd	sd	O	O
)	)	O	O
scores	scores	O	O
for	for	O	O
CGI-SF	cgi-sf	O	O
were	were	O	O
significantly	significantly	O	O
lower	lower	O	O
,	,	O	O
i.e.	i.e.	O	O
better	better	O	O
,	,	O	O
in	in	O	O
patients	patients	O	O
on	on	O	O
bupropion	bupropion	S_chemicals	O
SR	sr	O	O
,	,	O	O
at	at	O	O
2.4	2.4	O	O
(	(	O	O
1.2	1.2	O	O
)	)	O	O
,	,	O	O
than	than	O	O
in	in	O	O
the	the	O	O
placebo	placebo	O	O
group	group	O	O
,	,	O	O
at	at	O	O
3.9	3.9	O	O
(	(	O	O
1.1	1.1	O	O
)	)	O	O
(	(	O	O
P=	p=	O	O
0.01	0.01	O	O
)	)	O	O
.	.	O	O

Men	men	O	O
who	who	O	O
received	received	O	O
bupropion	bupropion	S_chemicals	O
had	had	O	O
a	a	O	O
significant	significant	O	O
increase	increase	O	O
in	in	O	O
the	the	O	O
total	total	O	O
IIEF	iief	O	O
score	score	O	O
(	(	O	O
54.4	54.4	O	O
%	%	O	O
vs	vs	O	O
1.2	1.2	O	O
%	%	O	O
;	;	O	O
P=	p=	O	O
0.003	0.003	O	O
)	)	O	O
,	,	O	O
and	and	O	O
in	in	O	O
the	the	O	O
five	five	O	O
different	different	O	O
domains	domains	O	O
of	of	O	O
the	the	O	O
IIEF	iief	O	O
.	.	O	O

Total	total	O	O
ASEX	asex	O	O
scores	scores	O	O
were	were	O	O
significantly	significantly	O	O
lower	lower	O	O
,	,	O	O
i.e.	i.e.	O	O
better	better	O	O
,	,	O	O
among	among	O	O
men	men	O	O
who	who	O	O
received	received	O	O
bupropion	bupropion	S_chemicals	O
than	than	O	O
placebo	placebo	O	O
,	,	O	O
at	at	O	O
15.5	15.5	O	O
(	(	O	O
4.3	4.3	O	O
)	)	O	O
vs	vs	O	O
21.5	21.5	O	O
(	(	O	O
4.7	4.7	O	O
)	)	O	O
(	(	O	O
P=	p=	O	O
0.002	0.002	O	O
)	)	O	O
.	.	O	O

The	the	O	O
EDITS	edits	O	O
scores	scores	O	O
were	were	O	O
67.4	67.4	O	O
(	(	O	O
10.2	10.2	O	O
)	)	O	O
for	for	O	O
the	the	O	O
bupropion	bupropion	S_chemicals	O
and	and	O	O
36.3	36.3	O	O
(	(	O	O
11.7	11.7	O	O
)	)	O	O
for	for	O	O
the	the	O	O
placebo	placebo	O	O
group	group	O	O
(	(	O	O
P=	p=	O	O
0.001	0.001	O	O
)	)	O	O
.	.	O	O

The	the	O	O
ASEX	asex	O	O
score	score	O	O
and	and	O	O
CGI-SF	cgi-sf	O	O
score	score	O	O
were	were	O	O
correlated	correlated	O	O
(	(	O	O
P=	p=	O	O
0.003	0.003	O	O
)	)	O	O
.	.	O	O

In	in	O	O
linear	linear	O	O
regression	regression	O	O
analyses	analyses	O	O
the	the	O	O
CGI-SF	cgi-sf	O	O
score	score	O	O
was	was	O	O
not	not	O	O
affected	affected	O	O
significantly	significantly	O	O
by	by	O	O
the	the	O	O
duration	duration	O	O
of	of	O	O
SD	sd	O	O
,	,	O	O
type	type	O	O
of	of	O	O
SSRI	ssri	O	O
used	used	O	O
and	and	O	O
age	age	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Bupropion	bupropion	S_chemicals	O
is	is	O	O
an	an	O	O
effective	effective	O	O
treatment	treatment	O	O
for	for	O	O
male	male	O	O
SD	sd	O	O
induced	induced	O	O
by	by	O	O
SSRIs	ssris	S_chemicals	O
.	.	O	O

These	these	O	O
results	results	O	O
provide	provide	O	O
empirical	empirical	O	O
support	support	O	O
for	for	O	O
conducting	conducting	O	O
a	a	O	O
further	further	O	O
study	study	O	O
of	of	O	O
bupropion	bupropion	S_chemicals	O
.	.	O	O

